Chief Executive Officer
Katherine Stueland has dedicated her career to transforming healthcare by leading patient-centric businesses. Her career has spanned supporting the FDA approval of several rare disease therapeutics, the first protease inhibitor for HIV/AIDS and the first cancer immunotherapy, all in partnership with the powerful voices of patient advocates. Katherine has been a central figure in moving healthcare forward by integrating genomic information to enhance the accuracy and effectiveness of diagnosing cancer and rare diseases.
In June 2021, Katherine was named President and CEO of GeneDx (Nasdaq: WGS), a company that emerged from the National Institutes of Health and today is transforming healthcare through genomic insights with a mission to end the diagnostic odyssey. GeneDx delivers personalized and actionable health insights to inform diagnosis, direct treatment and drug discovery. Since joining GeneDx, she focused the business on its industry-leading exome and genome testing and interpretation products, fueled by one of the world’s largest rare disease data sets. Under Katherine’s leadership, GeneDx has nearly tripled its sequencing capacity, completing over 750,000 exomes and genomes while achieving profitability and a market cap of nearly $3 billion.
Recognized for these achievements, Katherine was named to the 2025 CNBC Changemakers: Women Transforming Business List, and Fast Company recently named GeneDx one of its Most Innovative Companies of 2025. She is nominated for the Maryland Tech Council’s ICON Awards for Life Sciences CEO of the Year and GeneDx is nominated for Life Sciences Company of the Year. In 2023, Fierce Pharma recognized Katherine as one of the most influential people in biotech.
Katherine serves on the JED Foundation Leadership Council, a nonprofit organization that works to prevent suicide and protect the emotional health of young adults and teens as part of her lifetime commitment to help improve mental health. Katherine graduated from Miami University in Oxford, Ohio, with a bachelor’s degree in science and English literature.
